Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.
| Date | Candidate | Mechanism of action | Indication | Route | Modality | Development stage | Note | |
|---|---|---|---|---|---|---|---|---|
| 01/20/20 | GEM142 | Nrf2 Activator | COPD and Diabetic kidney disease | Oral | Small molecule | Phase 1 | A novel Nrf2 activator. Inhibited airway inflammation to a similar degree as roflumilast in a mouse smoke exposure model. Improved urinary albumin/creatinine ratio in STZ-induced rat diabetic model (Type I) and KK-Ay mouse (Type II) and inhibited damage of the renal tissues. Synergistic effects by combination with losartan on urinary albumin/creatinine ratio were noted in KK-Ay mice. No adverse events were seen in multiple dose phase 1 study even at 1000 mg/man/day. | Contact |
| 01/16/20 | GEM141 | Esophageal implant (See note) | Pediatric esophageal atresia and other conditions that affect the esophagus | Implant （auto- logous) | Cell therapy | IND ready | Esophageal implant made by combining a novel cell therapy platform (see TGEM38) with a patient’s own cells (haematopoietic stem and precursor cells). GEM141 leverages the body’s inherent capacity to heal itself as it is a “living tube” that facilitates regeneration of esophageal tissue and triggers a positive host response resulting in a tissue-engineered neo-conduit that restores continuity of the esophagus. These implants have the potential to dramatically improve the quality of life for children and adults | Contact |
| 01/08/20 | GEM140 | Limbal stem cells | Intractable limbal stem cell deficiency | Implan- tation | Cell therapy | Clinical | Establishment and production of limbus-derived epithelial cell plate manufacturing process in GMP facility with excellent economic feasibility. Phase 1 study is currently in progress. |
Contact |
| 01/08/20 | GEM139 | Staphylococcus aureus vaccine | Staphylococcus aureus infection | s.c. | Vaccine | Preclinical | The vaccine comprising antigens and toxin is being developed. The candidate antigens to block the immune-evasion pathway by MSCRAMMs and toxin of S. aureus have already been defined. | Contact |
| 12/24/19 | GEM138 | Biosimilar adalimumab | Same indications as adalimumab | i.v. | Antibody | Preclinical | Purified GEM138 is highly similar to ranibizumab by SDS-PAGE. GEM138 and adalimumab show a similar response in a TNF-a ELISA assay. Plant-based technology (TGEM036) was applied for production of GEM138. | Contact |
| 12/24/19 | GEM137 | Biosimilar ranibizumab | Same indications as ranibizumab | intra- vetreal | Antibody | Preclinical | Peptide mapping by Mass Spectrometry confirms amino acid sequence identity of GEM137 with ranibizumab. Purified GEM137 is highly similar to ranibizumab by SDS-PAGE. Ligand (rVEGF) biding by GEM137 demonstrated to be similar to ranibizumab by ELISA. Plant-based technology (TGEM036) was applied for production of GEM137. | Contact |
| 12/24/19 | GEM136 | Biosimilar trastuzumab | Same indications as trastuzumab | i.v. | Antibody | Preclinical | GEM136 N-terminal sequences are identical to trastuzumab. Levels of contaminating proteins, profiles of breakdown products and inhibitory activity to trastuzumab on in vitro growth of hER2 positive breast cancer cell line are similar between GEM136 and trastuzumab. Plant-based technology (TGEM036) was applied for production of GEM136. | Contact |
| 12/20/19 | GEM135 | Inhibition of proteasome via novel target | Multiple tumors | i.v., i.p. and Oral | Small molecule | Preclinical | Novel target different from that for all the commercially available proteasome inhibitors. Works against many cancer cell lines tested including bortezomib, cisplatin and paclitaxel resistant cell lines. Significant therapeutic window between cancer and normal cells. Favorable toxicity profile. Regressed tumor growth and prolonged survival on syngeneic and xenograft mouse models. Expected to be effective against solid tumors without off target effects and peripheral neuropathy. Two lead compounds are being developed. | Contact |
| 12/06/19 | GEM134 | Anti-CD147 antibody | Hematological （AML, MM etc）and solid tumors（liver, colon, lung etc） | i.v. | Antibody | Preclinical | Fully human antibody binding to human/ cynomolgus CD147. Has been shown to be very effective in various types of cancers in vivo xenograft mouse model. ADCC activity mainly contributes to the anti-tumor effect. |
Contact |
| 11/29/19 | GEM058 | Increase cellular ATP and promote wound healing | Diabetes foot ulcer | Topical | Small molecules | Phase 2 completed | Reducing inflammation of endothelial cells of blood vessels. Increasing cellular ATP and speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. The arrangement of actin which is essential for cell migration is ATP dependent. Applicable to all kind of wound and low cost treatment |
Contact |